Background Immuno-oncology (IO) agents and tyrosine kinase inhibitors (TKIs) have
revolutionized the treatment paradigm for metastatic renal cell carcinoma (mRCC). Data on …

Purpose Management of metastatic renal cell cancer (mRCC) has undergone a paradigm
shift with immune-checkpoint inhibitors (ICI) in the first-line setting. However, direct …

Abstract Background Immune-Oncology (IO) therapies have changed first-line (1L) treatment
paradigm for metastatic renal cell carcinoma (mRCC) in last few years with robust clinical …

Introduction Combination immune checkpoint inhibitors (ICI) and vascular endothelial
growth factor receptor tyrosine kinase inhibitors (VEGF-R-TKI), including pembrolizumab …

The treatment landscape of metastatic renal cell carcinoma (mRCC) has been transformed
with the advent of antiangiogenics, notably tyrosine kinase inhibitors (TKIs) targeting …

Context There have been substantial changes in the management of patients with metastatic
renal cell carcinoma (mRCC) over the past decade, with upfront immunotherapy-based …

Combination treatments with immuno-oncology (IO) agents and IO agents plus a vascular
endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI) have been …

Purpose: Four recent first-line clinical trials leveraging immune-oncology agents
demonstrated an overall survival (OS) benefit relative to sunitinib. We aimed to provide …

Background Immune checkpoint inhibitor/tyrosine kinase inhibitor (ICI/TKI) combinations are
a new standard of care for the initial treatment of metastatic renal cell carcinoma (mRCC) …

Purpose Current systemic treatment of targeted therapies, namely the vascular endothelial
growth factor-antibody (VEGF-AB), VEGF receptor tyrosine kinase inhibitor (TKI) and …